Search

Your search keyword '"Letoublon C"' showing total 79 results
Start Over Author "Letoublon C" Search Limiters Peer Reviewed
79 results on '"Letoublon C"'

2. Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers

Author

Nomi, T., Oudafal, N., Kawai, T., Komatsu, S., Okumura, S., Petrucciani, N., Laurent, A., Bucur, P., Barbier, L., Trechot, B., Nunèz, J., Tedeschi, M., Allard, M.-A., Golse, N., Ciacio, O., Pittau, G., Sa Cunha, A., Adam, R., Laurent, C., Chiche, L., Leourier, P., Rebibo, L., Regimbeau, J.-M., Ferre, L., Souche, F.R., Chauvat, J., Fabre, J.-M., Jehaes, F., Mohkam, K., Lesurtel, M., Ducerf, C., Mabrut, J.-Y., Hor, T., Paye, F., Balladur, P., Suc, B., Muscari, F., Millet, G., El Amrani, M., Ratajczak, C., Lecolle, K., Boleslawski, E., Truant, S., Pruvot, F.-R., Kianmanesh, A.-R., Codjia, T., Schwarz, L., Girard, E., Abba, J., Letoublon, C., Chirica, M., Carmelo, A., VanBrugghe, C., Cherkaoui, Z., Unterteiner, X., Memeo, R., Pessaux, P., Buc, E., Lermite, E., Barbieux, J., Bougard, M., Marchese, U., Ewald, J., Turini, O., Thobie, A., Menahem, B., Mulliri, A., Lubrano, J., Zemour, J., Fagot, H., Passot, G., Gregoire, E., Hardwigsen, J., le Treut, Y.-P., Patrice, D., Hobeika, Christian, Fuks, David, Cauchy, François, Goumard, Claire, Gayet, Brice, Laurent, Alexis, Soubrane, Olivier, Salamé, Ephrem, Cherqui, Daniel, Regimbeau, Jean-Marc, Mabrut, Jean-Yves, Scatton, Olivier, and Vibert, Eric

Published
2020
Full Text
View/download PDF

4. Influence de 4 solutions de préservation sur la durée de réanimation, la survie du greffon et du patient après transplantation hépatique

Author

Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, S., Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C., Salloum, C., Chirica, M., Abba, J., Letoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Savier, E., Brustia, R., Golmard, J.-L., and Scatton, O.

Published
2020
Full Text
View/download PDF

5. Influence of 4 preservation solutions on ICU stay, graft and patient survival following liver transplantation

Author

Mallet, A., Cherqui, D., Adam, R., Ciacio, O., Pittau, G., Trechot, B., Boudjema, K., Houssel-Debry, P., Merdignac, A., Rayar, M., Soubrane, O., Dokmak, S., Dondero, F., Sepulveda, A., Bachellier, P., Addeo, P.-F., Faitot, F., Navarro, F., Herrero, A., Jaber, S., Pageaux, G.-P., Vaillant, J.-C., Rousseau, G., Siksik, J.-M., Le Treut, Y.P., Gregoire, E., Hardwigsen, J., Compagnon, P., Lim, C., Salloum, C., Chirica, M., Abba, J., Letoublon, C., Pruvot, F.-R., Boleslawski, E., Salame, E., Barbier, L., Mabrut, J.Y., Mohkam, K., Suc, B., Maulat, C., Chiche, L., Laurent, C., Jeune, F., Perdigao, F., Dao, T., Mulliri, A., Gugenheim, J., Boilot, O., Buc, E., Branchereau, S., Chardot, C., Heyd, B., Savier, E., Brustia, R., Golmard, J.-L., and Scatton, O.

Published
2020
Full Text
View/download PDF

21. La résection des orifices de trocart améliore-t-elle la survie des patients atteints de cancer vésiculaire de découverte fortuite ? Rapport AFC-CVB-2009

Author

Fuks, D., Regimbeau, J.-M., Pessaux, P., Bachellier, P., Raventos, A., Mantion, G., Gigot, J.-F., Chiche, L., Pascal, G., Azoulay, D., Laurent, A., Letoublon, C., Boleslawski, E., Rivoire, M., Mabrut, J.-Y., Adham, M., Le Treut, Y.-P., Delpero, J.-R., Navarro, F., Ayav, A., Boudjema, K., Nuzzo, G., Scotte, M., and Farges, O.

Published
2013
Full Text
View/download PDF

38. EGFR in colorectal cancer: more than a simple receptor

Author

Francoual, M., Etienne-Grimaldi, M.-C., Formento, J.-L., Benchimol, D., Bourgeon, A., Chazal, M., Letoublon, C., André, T., Gilly, N., Delpero, J.-R., Lasser, P., Spano, J.-P., and Milano, G.

Published
2006

44. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Author

Nordlinger, B, Sorbye, H, Glimelius, B, Poston, Gj, Schlag, Pm, Rougier, P, Bechstein, Wo, Primrose, Jn, Walpole, Et, FINCH JONES, M, Jaeck, D, Mirza, D, Parks, Rw, Collette, L, Praet, M, Bethe, U, VAN CUTSEM, E, Scheithauer, W, Gruenberger, T, Hohenberger, W, Iveson, T, Karner, J, Levi, J, Hugh, T, DE GREVE, J, Chan, A, Davidson, B, Lindner, P, Peeters, M, Stein, B, Diamond, T, Ducreux, M, Lasser, P, Graeven, U, Paillot, B, Doran, J, Gouillat, C, Iesalnieks, I, Jauch, Kw, JAGOT LACOUSSIERE, P, Jansen, Rl, Koehne, H, Konopke, R, Otto, F, Sherlock, D, VAN HAZEL, G, Ackland, S, Bedenne, L, Bories, E, CLAVERO FABRI MC, Conroy, T, KAMINSKY FORRETT MC, Husseini, F, Karapetis, C, Mãœller, L, Price, T, Rosenberg, R, Schott, J, Tschmelitsch, J, VAN LAETHEM JL, Wals, J, Weimann, A, Arnaud, Jp, Arsene, D, Auby, D, Bhattacharya, S, Cebon, E, Cherqui, D, Confente, C, Dousset, B, Frickhofen, N, Frilling, A, Evan, P, Ganju, V, Hã–ffken, K, Lazorthes, F, Letoublon, C, Madroszyk, A, Nitti, Donato, Orr, B, Pariente, Ea, Pector, Jc, Raoul, Jl, Rees, M, Ridwelski, K, Rouanet, P, Toogood, Gj, Vergauwe, P, Wilke, Hj, Kaplan, R, Horiot, Jc, Littbrand, B, Awada, A, Stenning, S, Lejeune, F., Haukeland University Hospital, University of Bergen (UiB), Uppsala Universitet [Uppsala], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Chirurgie Viscérale, Hépatique et de Transplantation Multiorganes, Université Louis Pasteur - Strasbourg I, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), University Hospitals Leuven [Leuven], Centre Énergétique et Procédés (CEP), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), and Université d'Angers (UA)

Subjects
Adult, Male, medicine.medical_specialty, Organoplatinum Compounds, Colorectal cancer, [SDV]Life Sciences [q-bio], 030230 surgery, Perioperative Care, 03 medical and health sciences, 0302 clinical medicine, Hepatic arterial infusion, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, business.industry, Liver Neoplasms, Hazard ratio, Cancer, General Medicine, Perioperative, Middle Aged, medicine.disease, Combined Modality Therapy, 3. Good health, Surgery, Oxaliplatin, Clinical trial, 030220 oncology & carcinogenesis, Female, Fluorouracil, Colorectal Neoplasms, Liver cancer, business, medicine.drug
Abstract

Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Methods This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0·71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479. Findings In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1–6) preoperative cycles and 115 (63%) patients received a median six (1–8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7·3% (from 28·1% [95·66% CI 21·3–35·5] to 35·4% [28·1–42·7]; HR 0·79 [0·62–1·02]; p=0·058) in randomised patients; 8·1% (from 28·1% [21·2–36·6] to 36·2% [28·7–43·8]; HR 0·77 [0·60–1·00]; p=0·041) in eligible patients; and 9·2% (from 33·2% [25·3–41·2] to 42·4% [34·0–50·5]; HR 0·73 [0·55–0·97]; p=0·025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0·04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group. Interpretation Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis.

Published
2008
Full Text
View/download PDF

46. Long-term outcomes of patients with 10 or more colorectal liver metastases.

Author

Allard, M A, Adam, R, Giuliante, F, Lapointe, R, Hubert, C, Ijzermans, J N M, Mirza, D F, Elias, D, Laurent, C, Gruenberger, T, Poston, G, Letoublon, C, Isoniemi, H, Lucidi, V, Popescu, I, and Figueras, J

Abstract

Background: Although the number of colorectal liver metastases (CLM) is decreasingly considered as a contraindication to surgery, patients with 10 CLM or more are often denied liver surgery. This study aimed to evaluate the outcome after liver surgery and to identify prognostic factors of survival in such patients.Methods: The study population consisted of a multicentre cohort of patients with CLM (N=12 406) operated on, with intention to resect, from January 2005-June 2013 and whose data were prospectively collected in the LiverMetSurvey registry.Results: Overall, the group ⩾10 CLM (N=529, 4.3%) experienced a 5-year overall survival (OS) of 30%. A macroscopically complete (R0/R1) resection (72.8% of patients) was associated with a 3- and 5-year OS of 61% and 39% vs 29% and 5% for R2/no resection patients (P<0.0001). At multivariate analysis, R0/R1 resection emerged as the strongest favourable factor of OS (HR 0.35 (0.26-0.48)). Other independent favourable factors were as follows: maximal tumour size <40 mm (HR 0.67 (0.49-0.92)); age <60 years (HR 0.66 (0.50-0.88)); preoperative MRI (HR 0.65 (0.47-0.89)); and adjuvant chemotherapy (HR 0.73 (0.55-0.98)). The model showed that 5-year OS rates of 30% was possible provided R0/R1 resection associated with at least an additional favourable factor.Conclusions: Liver resection might provide long-term survival in patients with ⩾10 CLM staged with preoperative MRI, provided R0/R1 resection followed by adjuvant therapy. A validation of these results in another cohort is needed. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

49. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.

Author

Etienne-Grimaldi, M-C, Mahamat, A, Chazal, M, Laurent-Puig, P, Olschwang, S, Gaub, M-P, Formento, J-L, Formento, P, Sudaka, A, Boige, V, Abderrahim-Ferkoune, A, Benchimol, D, André, T, Houry, S, Faucheron, J-L, Letoublon, C, Gilly, F-N, Delpero, J-R, Lasser, P, and Pradere, B

Abstract

Background: To test the prognostic value of tumour protein and genetic markers in colorectal cancer (CRC) and examine whether deficient mismatch repair (dMMR) tumours had a distinct profile relative to proficient mismatch repair (pMMR) tumours.Methods: This prospective multicentric study involved 251 stage I-III CRC patients. Analysed biomarkers were EGFR (binding assay), VEGFA, thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) expressions, MMR status, mutations of KRAS (codons 12-13), BRAF (V600E), PIK3CA (exons 9 and 20), APC (exon 15) and P53 (exons 4-9), CpG island methylation phenotype status, ploidy, S-phase, LOH.Results: The only significant predictor of relapse-free survival (RFS) was tumour staging. Analyses restricted to stage III showed a trend towards a shorter RFS in KRAS-mutated (P=0.005), BRAF wt (P=0.009) and pMMR tumours (P=0.036). Deficient mismatch repair tumours significantly demonstrated higher TS (median 3.1 vs 1.4) and TP (median 5.8 vs 3.5) expression relative to pMMR (P<0.001) and show higher DPD expression (median 14.9 vs 7.9, P=0.027) and EGFR content (median 69 vs 38, P=0.037) relative to pMMR.Conclusions: Present data suggesting that both TS and DPD are overexpressed in dMMR tumours as compared with pMMR tumours provide a strong rationale that may explain the resistance of dMMR tumours to 5FU-based therapy. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results